KANATA, Ontario– BWX Technologies, Inc. (NYSE: BWXT) has appointed Vittorio Puppo as president of BWXT Medical Ltd., effective August 12, 2024. In his new role,
(OTTAWA, Ontario and Beloit, WI – July 22, 2024) – BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT) and NorthStar Medical Radioisotopes,
(OTTAWA, Ontario – June 7, 2024) – BWXT Medical Ltd. has submitted a Drug Master File (DMF) to the U.S. Drug and Food Administration (FDA)
Agreement Furthers BWXT Medical’s Position as a Global Leader in Actinium Supply Collaboration Enables Fusion to Produce High Purity Actinium-225 At Its Manufacturing Facility for
(Ottawa, Ontario – February 1, 2023) – Life-saving Molybdenum-99 (Mo-99) isotopes can now be produced at Ontario Power Generation’s (OPG) Darlington Nuclear Generating Station, thanks
Company Highlights Growing Nuclear Medicine Product Portfolio and Future Opportunities in Therapeutic Radioisotopes (OTTAWA, ON – September 13, 2022) – BWX Technologies, Inc. (NYSE: BWXT)
(OTTAWA, ON – June 27, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has executed a commercial agreement with
(OTTAWA, ON – June 13, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. and TRIUMF, Canada’s particle accelerator centre,
(LYNCHBURG, Va. – March 8, 2021) – BWXT Medical Ltd. (BWXT Medical) and Global Medical Solutions, Ltd. (GMS) have entered into a joint venture (JV)
(LYNCHBURG, Va. – Feb. 1, 2021) – BWX Technologies, Inc. (NYSE: BWXT) today announced that its subsidiary BWXT ITG Canada, Inc., a nuclear medicine company,